Advertisement inVentiv Q2 net revenue rises - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

inVentiv Q2 net revenue rises

inVentiv Health, a contract research organization (CRO), has reported net revenue of $308.99m for the second quarter ended 30 June 2011, an increase of 25.1%, compared to $246.92m for the same period in 2010.

The company has posted a net loss of $3.31m for the second quarter of 2011, compared to $9.94m for the same period in 2010.

inVentiv’s operating income was $16.53m, compared to $22.08m for the same period prior year.

For the six months ended 30 June 2011, the company reported net revenue of $580.79m, compared to $476.53m for the same period in 2010.

inVentiv has reported net income of $11.73m for the six months ended 30 June 2011, compared to $20.29m for the same period in 2010.

For the six months ended 30 June 2011, the company’s operating income was $21.3m, compared to $43.87m for the same period prior year.

inVentiv Health CEO Paul Meister said they continue to pursue options to strengthen their presence in established and emerging markets, including Japan, and in high-priority countries such as China and India.

"Additionally, we remain focused on improving efficiencies and executing on our strategic objectives in all three of our segments: Clinical, Commercial and Consulting," Meister said.